TEVA

Teva Pharmaceutical Industries Ltd. (TEVA)

Market Closed
15 Dec, 15:14
TASE TASE
9,683. 00
ILA
+93
+0.97%
ILA
20.84B Market Cap
- P/E Ratio
0.34% Div Yield
1,001,905 Volume
- Eps
9,590 ILA
Previous Close
Day Range
9,540 9,750
Year Range
4,865 9,750
Want to track TEVA and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 43 days

Summary

TEVA closed today higher at 9,683 ILA, an increase of 0.97% from yesterday's close, completing a monthly increase of 7.53% or 678 ILA. Over the past 12 months, TEVA stock gained 19.32%.
TEVA is not paying dividends to its shareholders.
The last earnings report, released on Nov 05, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports. The next scheduled earnings report is due on Jan 27, 2026.
Teva Pharmaceutical Industries Ltd. has completed 4 stock splits, with the recent split occurring on Jun 27, 2004.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on TASE (ILA).

TEVA Chart

Teva Pharmaceutical Industries Ltd. (TEVA) FAQ

What is the stock price today?

The current price is 9,683.00 ILA.

On which exchange is it traded?

Teva Pharmaceutical Industries Ltd. is listed on TASE.

What is its stock symbol?

The ticker symbol is TEVA.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0.34%.

What is its market cap?

As of today, the market cap is 20.84B.

When is the next earnings date?

The next earnings report will release on Jan 27, 2026.

Has Teva Pharmaceutical Industries Ltd. ever had a stock split?

Teva Pharmaceutical Industries Ltd. had 4 splits and the recent split was on Jun 27, 2004.

Teva Pharmaceutical Industries Ltd. Profile

Specialty Retail Industry
Consumer Discretionary Sector
Richard D. Francis CEO
TASE Exchange
IL0006290147 ISIN
IL Country
37,000 Employees
- Last Dividend
27 Jun 2004 Last Split
- IPO Date

Overview

Teva Pharmaceutical Industries Limited is a prominent global company with a focus on developing, manufacturing, marketing, and distributing a wide range of pharmaceutical products. Its operations span across North America, Europe, Israel, and other international markets. Teva's portfolio includes generic medicines, specialty medicines, and biopharmaceutical products, catering to various dosage forms and therapeutic areas. With a history dating back to 1901, the company has established itself as a leader in the pharmaceutical industry, headquartered in Tel Aviv, Israel. Teva is known for its contribution to central nervous system (CNS), respiratory, and oncology therapeutic areas, providing active pharmaceutical ingredients and contract manufacturing services, alongside operating an out-licensing platform for other pharmaceutical companies. Teva's commitment to healthcare and therapeutic advancements is evident through its collaboration agreements with MedinCell, Sanofi, Alvotech, and Biolojic Design Ltd., as well as a license agreement with MODAG GmbH.

Products and Services

BENDEKA and TREANDA injections: Used for the treatment of chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma, these injections underscore Teva's focus on oncology.

GRANIX, TRISENOX, LONQUEX, and TEVAGRASTIM/RATIOGRASTIM: These products exemplify Teva's commitment to providing supportive care in oncology, including treatments for neutropenia and arsenic trioxide for leukemia.

COPAXONE: This flagship product for the treatment of relapsing forms of multiple sclerosis highlights Teva's innovation in CNS therapies.

AJOVY: A treatment for the preventive care of migraine in adults, AJOVY is part of Teva's specialty medicine range aimed at improving quality of life for migraine sufferers.

AUSTEDO: Focused on neurodegenerative and movement disorders, AUSTEDO is used for treating conditions associated with Huntington's disease and tardive dyskinesia.

UZEDY: This antipsychotic is used for the treatment of schizophrenia, reflecting Teva's ongoing development in CNS health.

Respiratory Products: Teva offers a suite of respiratory products like ProAir RespiClick inhalation powder, QVAR for asthma, BRALTUS, CINQAIR/CINQAERO injection, DuoResp Spiromax, and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder, addressing a broad spectrum of respiratory conditions.

OTC Products: Teva's over-the-counter (OTC) offerings under brands such as SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA, cater to a variety of everyday health needs, from skincare to cold and flu relief.

In addition to its broad spectrum of pharmaceutical products, Teva Pharmaceutical Industries Limited also provides active pharmaceutical ingredients and contract manufacturing services, demonstrating its versatility and comprehensive approach to healthcare solutions.

Contact Information

Address: 124 Dvora Hanevi'a Street
Phone: 972 3 914 8213